StockData
LB Pharmaceuticals Inc logo

LB Pharmaceuticals Inc (LBRX) shareholders

LBRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/30
$40.30−2.69 (-6.26%)

Close on Nov 17, 2026Market cap $1.30BP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
95.5%
31M of 32M shares
Institutional holders
115
43 new, 3 sold out
Net institutional buying
3M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
David Kroin
Joint filing with Deep Track Capital, LP (11.70%), Deep Track Biotechnology Master Fund, Ltd. (9.40%)
3,352,80411.70%13D (active) amendmentFeb 6, 2025
Rajeev Shah
Joint filing with RA Capital Management, L.P. (8.70%), Peter Kolchinsky (8.70%) and 1 more
2,208,6048.70%13G (passive) amendmentDec 31, 2025
Robert Egen Atkinson
Joint filing with Commodore Capital LP (6.80%), Commodore Capital Master LP (6.80%) and 1 more
1,972,3696.80%13G (passive) amendmentMar 31, 2026
TCG Crossover GP II, LLC
Joint filing with TCG Crossover Fund II, L.P. (6.40%), Chen Yu (6.40%)
1,839,4896.40%13G (passive) amendmentMar 31, 2026
BlackRock, Inc.1,796,5436.30%13G (passive) amendmentJun 30, 2026
RA Capital Management, L.P.
Joint filing with Peter Kolchinsky (7.50%), Rajeev Shah (7.50%) and 1 more
1,675,0007.50%13G (passive)Sep 12, 2025
JPMorgan Chase & Co1,497,2935.20%13G (passive)Jun 30, 2026
Chen Yu
Joint filing with TCG Crossover GP II, LLC (5.00%), TCG Crossover Fund II, L.P. (5.00%)
1,447,3105.00%13G (passive) amendmentJun 30, 2026
Johnson David Edward
Joint filing with Caligan Partners LP (5.00%)
1,438,0705.00%13G (passive)Mar 31, 2026
Tomer Kariv
Joint filing with Pontifax Management 4 G.P. (2015) Ltd. (6.30%), Pontifax VI G.P. L.P. (6.30%) and 1 more
1,411,6816.30%13D (active)Sep 12, 2025
Trails Edge Capital Partners, LP
Joint filing with Trails Edge Biotechnology Master Fund, LP (5.00%), Ortav Yehudai (5.00%)
1,268,2655.00%13G (passive)Dec 24, 2025
Commodore Capital Master LP
Joint filing with Commodore Capital LP (5.50%), Robert Egen Atkinson (5.50%) and 1 more
1,225,0005.50%13G (passive)Sep 11, 2025

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of LBRXValueChange% of portfolio
Deep Track Capital, LP3,352,80410.39%$108.82M–1.58%
BlackRock, Inc.2,734,3058.48%$88.74M+263,4600.00%
Ra Capital Management, L.P.2,208,6046.85%$71.68M–0.62%
Nantahala Capital Management, LLC2,105,7886.53%$68.34M+1,052,8941.14%
Trails Edge Capital Partners, LP1,523,0224.72%$49.43M+203,6607.85%
Commodore Capital LP1,500,0004.65%$48.68M–2.90%
JPMorgan Chase & Co1,497,2934.64%$48.87M+69,7250.00%
TCG Crossover Management, LLC1,447,3104.49%$46.97M−392,1791.13%
Caligan Partners LP1,438,0704.46%$46.67M–2.20%
Spruce Street Capital LP1,376,1594.27%$44.66M–8.76%
Vanguard Capital Management LLC971,1653.01%$31.52M+76,5120.00%
Balyasny Asset Management L.P.921,4712.86%$29.91M−2,2230.04%
Alyeska Investment Group, L.P.863,9472.68%$28.04M–0.07%
Vivo Capital, LLC800,0002.48%$25.96M–2.37%
Nan Fung Group Holdings Ltd630,6571.95%$20.47M–15.57%
Geode Capital Management, LLC612,7931.90%$19.89M+94,5650.00%
State Street Corp602,0281.87%$19.54M+97,6550.00%
Logos Global Management LP585,0001.81%$18.99M−330,0000.82%
Goldman Sachs Group Inc576,4561.79%$18.71M+212,6570.00%
Jennison Associates LLC540,9021.68%$17.55M+2,6860.01%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 202611531M95.5%43 / 4213 / 34M1M
Q1 20267728M87.6%20 / 3114 / 106M1M
Q4 20256825M76.8%33 / 1213 / 167M3M
Q3 20255321M65.0%53 / 00 / 021M0M

Top mutual fund and ETF holders

Latest monthly portfolio reports (Form N-PORT)

121 funds held LBRX in Q2 2026, 43% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.

FundShares% of LBRXValue% of fundAs of
JPMorgan Small Cap Growth Fund692,9052.15%$22.49M0.86%Jun 30, 2026
Vanguard Total Stock Market Index Fund672,0002.08%$21.81M0.00%Jun 30, 2026
iShares Russell 2000 ETF581,7501.80%$18.88M0.02%Jun 30, 2026
BlackRock Health Sciences Opportunities Portfolio567,6271.76%$15.88M0.27%May 29, 2026
Vanguard Extended Market Index Fund278,8870.86%$9.05M0.01%Jun 30, 2026
Fidelity Small Cap Index Fund244,9100.76%$9.82M0.03%Jul 31, 2026
PGIM Jennison Health Sciences Fund231,1500.72%$6.47M0.47%May 29, 2026
JPMorgan Small Cap Blend Fund220,2410.68%$7.15M0.42%Jun 30, 2026
Select Biotechnology Portfolio187,7310.58%$5.25M0.10%May 31, 2026
Calamos Timpani Small Cap Growth Fund144,3260.45%$5.78M0.75%Jul 31, 2026
Fidelity Extended Market Index Fund126,2320.39%$3.53M0.01%May 31, 2026
Schwab U.S. Small-Cap ETF115,6590.36%$3.23M0.01%May 31, 2026
Multi-Manager Small Cap Equity Strategies Fund109,8190.34%$3.07M0.24%May 31, 2026
iShares Russell 2000 Value ETF107,4750.33%$3.49M0.02%Jun 30, 2026
State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF105,1710.33%$3.41M0.80%Jun 30, 2026

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Heather D. TurnerChief Executive Officer, Director––Sep 12, 2025
Susan Gani KozauerChief Medical Officer––Oct 13, 2026
Joseph M. MillerChief Financial Officer––Oct 13, 2026
Panandiker Kaya Kamlesh PaiChief Commercial Officer––Dec 11, 2025
Marc L. PanoffSenior Vice President, Finance10,2420.03%Sep 29, 2025
Gad SofferChief Business Officer––Sep 12, 2025
Anna EramoChief Medical Officer3,5850.01%Sep 12, 2025
Richard Anthony SilvaSVP, Technical Operations––Sep 12, 2025
Robert R. RuffoloDirector2,3650.01%Jun 5, 2026
Rekha HemrajaniDirector––Jun 5, 2026
William P. Kane JrDirector––Jun 5, 2026
Ran NussbaumDirector1,411,6814.38%Jun 5, 2026
Rebecca LuseDirector––Jun 5, 2026
Robert A. LenzDirector––Jun 5, 2026
J. Scott GarlandDirector––Jun 5, 2026
Zachary PrenskyDirector61,2740.19%Sep 12, 2025
David Kroin10% owner––Aug 3, 2026
Deep Track Biotechnology Master Fund, Ltd.10% owner––Aug 3, 2026
Deep Track Capital, LP10% owner3,352,80410.39%Aug 3, 2026
Deep Track Special Opportunities Fund, LP10% owner666,6662.07%Feb 10, 2026
Vida Ventures GP III, L.L.C.10% owner550,3441.71%Sep 16, 2025
Arie Belldegrun10% owner1,4340.00%Sep 16, 2025
Management 4 G.P. (2015) Ltd. Pontifax10% owner1,411,6814.38%Sep 16, 2025
Ventures Management Co. LLC Vida10% owner––Sep 16, 2025
Vida Ventures III, L.P.10% owner––Sep 16, 2025
Vida Ventures III-A, L.P.10% owner––Sep 16, 2025

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Ran Nussbaum
Director
Sep 12, 2025Buy+1,000,000$15.00$15.00M1,411,681
Ran Nussbaum
Director
Sep 12, 2025Conversion+411,681––411,681
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
Sep 12, 2025Buy+1,000,000$15.00$15.00M1,411,681
Management 4 G.P. (2015) Ltd. Pontifax
10% owner
Sep 12, 2025Conversion+411,681––411,681
Vida Ventures GP III, L.L.C.
10% owner
Sep 12, 2025Conversion+1,262––1,262
Vida Ventures GP III, L.L.C.
10% owner
Sep 12, 2025Conversion+547,648––547,648
Vida Ventures GP III, L.L.C.
10% owner
Sep 12, 2025Buy+767$15.00$11.51K2,029
Vida Ventures GP III, L.L.C.
10% owner
Sep 12, 2025Buy+332,566$15.00$4.99M880,214
Deep Track Capital, LP
10% owner
Sep 12, 2025Buy+666,666$15.00$10.00M666,666
Deep Track Capital, LP
10% owner
Sep 12, 2025Buy+2,000,000$15.00$30.00M2,686,138
Deep Track Capital, LP
10% owner
Sep 12, 2025Conversion+686,138––686,138

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of float
23.07%
6M shares short
Days to cover
18.0
At 0M shares a day
Change since last report
+11.4%
From 6M shares
Short volume, 20 days
59.2%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of LB Pharmaceuticals's stock actually held short. Settlement fails (shares not delivered on time) peaked at 40,000 shares on Sep 4, 2026 over the last 90 days.

Planned insider sales

Notices of proposed sale filed on Form 144 before shares are sold

SellerFiledSharesMarket valuePlanned saleAcquired through
Zachary Prensky
Former Officer
Jun 9, 202616,500$486.57KJun 9, 2026Owned Shares

See a number that looks wrong?